Version 1
: Received: 9 July 2024 / Approved: 10 July 2024 / Online: 10 July 2024 (10:17:58 CEST)
How to cite:
Li, X.; Liu, X.; Mao, J.; Liu, D.; Jiao, Z. Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients. Preprints2024, 2024070830. https://doi.org/10.20944/preprints202407.0830.v1
Li, X.; Liu, X.; Mao, J.; Liu, D.; Jiao, Z. Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients. Preprints 2024, 2024070830. https://doi.org/10.20944/preprints202407.0830.v1
Li, X.; Liu, X.; Mao, J.; Liu, D.; Jiao, Z. Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients. Preprints2024, 2024070830. https://doi.org/10.20944/preprints202407.0830.v1
APA Style
Li, X., Liu, X., Mao, J., Liu, D., & Jiao, Z. (2024). Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients. Preprints. https://doi.org/10.20944/preprints202407.0830.v1
Chicago/Turabian Style
Li, X., Dong Liu and Zheng Jiao. 2024 "Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients" Preprints. https://doi.org/10.20944/preprints202407.0830.v1
Abstract
Not occasional phamracokinetic variability and suboptimal exposure have been reported for micafungin in the intensive-care-unit (ICU) patients. This study aims to evaluate the quality of population pharmacokinetic models and provide rational using recommendation of this drug in clinical practice. Monte Carlo simulations were implemented to compare pharmakinetic parameters and probability of target attainment (PTA) towards various Candida species. Body weight, liver function, and SOFA score were the most frequent covariates in the final 16 included studies. micafungin clearance for ICU adults (SOFA≥10 or <10) was 39%–52% and 43%–57% higher, respectively, than non-ICU adults. For Candida infections with MICs <0.016 mg/L, the ICU group had lower proportions achieving PTA > 90% compared to the non-ICU group (2/6 (33%) vs. 4/7 (57%)), and for non-ICU and ICU adults, micafungin dosages of 100 and 150 mg were recommended, respectively. While for C. tropicalis and C. glabrata, 200 and 250 mg were recommended respectively. However, for C. krusei and C. parapsilosis, it failed to reach assumed PTA at MICs of 0.125-0.25 mg/L and 0.125-2 mg/L, respectively. Adjusting micafungin dosage in ICU patients may be necessary. Both ICU and non-ICU adults should modify their dosage regimens based on the Candida species and their respective MICs.
Keywords
micafungin; pharmacokinetic/pharmacodynamic; population pharmacokinetics; dosing regimen optimization
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
